China's Ally Bridge Group Participates in Tesaro's $155 Million Private Placement

Tesaro Inc., a Boston area oncology biotech, closed a $155 million private placement with participation from Ally Bridge Group, a China healthcare investment firm. Tesaro is developing immuno-oncological drugs based on technology in-licensed from AnaptysBio. Ally Bridge, which has invested in more than a dozen oncology companies based in the US, Europe and China, positioned the Tesaro investment as "an important partnership between ABG," and US-based Tesaro. More details... Stock Symbol: (NSDQ: TSRO) Share this with colleagues: // //